Loargys (pegzilarginase) | Relatório de avaliação de financiamento público disponível na Infomed | Indeferimento
sl.infarmed.pt/IZdKp
#infarmed #medicamentos #financiamentopublico #loargys #pegzilarginase
sl.infarmed.pt/IZdKp
#infarmed #medicamentos #financiamentopublico #loargys #pegzilarginase
September 29, 2026 at 9:20 AM
Loargys (pegzilarginase) | Relatório de avaliação de financiamento público disponível na Infomed | Indeferimento
sl.infarmed.pt/IZdKp
#infarmed #medicamentos #financiamentopublico #loargys #pegzilarginase
sl.infarmed.pt/IZdKp
#infarmed #medicamentos #financiamentopublico #loargys #pegzilarginase
B. Lee, L. Burrage et al set the scientific foundation for LOARGYS, now FDA approved to treat #arginaseDeficiency, a condition in which muscles of the legs, hips and pelvis are stiff, making it difficult to walk without help. Read the story: tinyurl.com/yfsc4xfe @bcmgenetics.bsky.social
Baylor College of Medicine researchers set the foundation for novel rare disease treatment
The story behind the discovery that led to the novel treatment revealed that scientific breakthroughs can sometimes happen in unexpected ways.
tinyurl.com
March 16, 2026 at 9:23 PM
B. Lee, L. Burrage et al set the scientific foundation for LOARGYS, now FDA approved to treat #arginaseDeficiency, a condition in which muscles of the legs, hips and pelvis are stiff, making it difficult to walk without help. Read the story: tinyurl.com/yfsc4xfe @bcmgenetics.bsky.social
Research @bcmgenetics.bsky.social helped lay the groundwork for LOARGYS, now FDA approved for the treatment of hyperargininemia in patients ages 2+ with Arginase 1 Deficiency (ARG1‑D), based on reduction of plasma arginine. Read the original From the Labs story: blogs.bcm.edu/2024/05/30/f...
blogs.bcm.edu
March 16, 2026 at 8:07 PM
Research @bcmgenetics.bsky.social helped lay the groundwork for LOARGYS, now FDA approved for the treatment of hyperargininemia in patients ages 2+ with Arginase 1 Deficiency (ARG1‑D), based on reduction of plasma arginine. Read the original From the Labs story: blogs.bcm.edu/2024/05/30/f...
FDA LOARGYS accelerated-approval milestone now shifts to confirmatory-evidence governance for ARG1-D ac... https://www.mattheneus.com/editorial/fda-loargys-arg1-deficiency-approval-trial1-lineage-accelerated-pathway-2026-03-23 #HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis
March 23, 2026 at 9:36 PM
FDA LOARGYS accelerated-approval milestone now shifts to confirmatory-evidence governance for ARG1-D ac... https://www.mattheneus.com/editorial/fda-loargys-arg1-deficiency-approval-trial1-lineage-accelerated-pathway-2026-03-23 #HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis
FDA grants accelerated approval to Loargys for arginase 1 deficiency with Trial 1 surrogate-endpoint basis https://www.mattheneus.com/editorial/fda-loargys-accelerated-approval-arg1-deficiency-trial1-lineage-2026-02-23 #HTA #RegulatoryAffairs #EvidenceSynthesis
March 13, 2026 at 6:18 PM
FDA grants accelerated approval to Loargys for arginase 1 deficiency with Trial 1 surrogate-endpoint basis https://www.mattheneus.com/editorial/fda-loargys-accelerated-approval-arg1-deficiency-trial1-lineage-2026-02-23 #HTA #RegulatoryAffairs #EvidenceSynthesis
Orsini Partners with Immedica Pharma to Launch Revolutionary Treatment for Rare Disease#United_States#Elk_Grove_Village#Orsini#Loargys#Immedica
Orsini Partners with Immedica Pharma to Launch Revolutionary Treatment for Rare Disease
Orsini has been chosen as the exclusive specialty pharmacy partner for Immedica Pharma's LOARGYS, focusing on rare diseases and innovative therapies.
third-news.com
March 9, 2026 at 1:25 PM
Orsini Partners with Immedica Pharma to Launch Revolutionary Treatment for Rare Disease#United_States#Elk_Grove_Village#Orsini#Loargys#Immedica
FDA Grants Accelerated Approval for Loargys® in Treating Hyperargininemia#United_States#Chicago#Loargys#Arginase_1_Deficiency#Immedica_Pharma
FDA Grants Accelerated Approval for Loargys® in Treating Hyperargininemia
Immedica Pharma announces FDA's accelerated approval for Loargys®, designed for patients 2 years and older with Arginase 1 Deficiency, addressing a critical need in metabolic disease treatment.
third-news.com
February 23, 2026 at 7:42 PM
FDA Grants Accelerated Approval for Loargys® in Treating Hyperargininemia#United_States#Chicago#Loargys#Arginase_1_Deficiency#Immedica_Pharma
